Article Correctness Is Author's Responsibility: Study shows long-term survival benefit for certain patients with advanced lung cancer

(Yale University) According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).